News coverage about DelMar Pharmaceuticals (NASDAQ:DMPI) has trended somewhat positive this week, according to Accern Sentiment Analysis. Accern ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. DelMar Pharmaceuticals earned a news impact score of 0.18 on Accern’s scale. Accern also gave press coverage about the company an impact score of 45.724460642636 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

DelMar Pharmaceuticals (NASDAQ DMPI) opened at 1.68 on Thursday. The stock’s 50 day moving average price is $2.08 and its 200-day moving average price is $3.14. DelMar Pharmaceuticals has a one year low of $1.59 and a one year high of $7.54.

DelMar Pharmaceuticals (NASDAQ:DMPI) last posted its quarterly earnings results on Thursday, May 18th. The company reported ($0.18) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.18). Analysts predict that DelMar Pharmaceuticals will post ($0.72) EPS for the current fiscal year.

DMPI has been the topic of a number of research analyst reports. Maxim Group reaffirmed a “buy” rating and set a $11.00 price target on shares of DelMar Pharmaceuticals in a report on Friday, June 23rd. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of DelMar Pharmaceuticals in a report on Tuesday, May 30th.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at

DelMar Pharmaceuticals Company Profile

DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.

Receive News & Ratings for DelMar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.